I[NTRODUCTION]{.smallcaps} {#sec1-1}
==========================

Obstructive sleep apnea (OSA) is characterized by recurrent complete or partial upper airway obstruction, resulting in intermittent hypoxemia and arousals from sleep.\[[@ref1]\] OSA has been associated with increased risk for cardiovascular disease including atherothrombotic diseases such as stroke and coronary artery disease (CAD).\[[@ref2]\] Moreover, our previous study documented a high prevalence of moderate-to-severe OSA among patients undergoing coronary stent implantation, and OSA was associated with increased 2-year composite major adverse cardiovascular events (MACEs) rate.\[[@ref3]\]

The pathophysiological mechanisms underlying the association between OSA and cardiovascular disease remain to be elucidated. Some have proposed that the repeated cycles of intermittent hypoxemia, sympathetic activation, and sleep disruption caused by OSA may lead to vascular abnormalities including endothelial dysfunction, vascular inflammation, and increased platelet activation and aggregation in the general population.\[[@ref4]\] Higher mean platelet volume (MPV)\[[@ref5]\] and decreased platelet-to-lymphocyte ratio\[[@ref6]\] also have been documented among patients with OSA, indicating the important role of platelet activation and aggregation.

Patients undergoing percutaneous coronary intervention (PCI) are a special population receiving a loading dose of antiplatelet agents (such as aspirin and clopidogrel) before the index procedure as well as a long-term maintenance dose to avoid stent thrombosis, especially for drug-eluting stents (DESs).\[[@ref7]\] Although the antiplatelet effect of the latter drugs might be decreased in PCI patients with OSA in possible association with higher risk of stent thrombosis, the relationship between OSA and platelet reactivity in patients undergoing DES implantation with loading doses of antiplatelet agents has not been defined and is the subject of the present study.

M[ETHODS]{.smallcaps} {#sec1-2}
=====================

Ethical approval {#sec2-1}
----------------

The procedure was approved by the Institutional Ethics Committee of Nanjing First Hospital, and in accordance with the *Helsinki Declaration* of 1975, as revised in 2000. The written informed consent was obtained from all patients.

Study population {#sec2-2}
----------------

A total of 340 patients in Nanjing First hospital were enrolled in this study from October 2012 to April 2014 within the framework of a previously reported trial.\[[@ref3]\] All enrolled individuals were treated with DES implantation in at least one major epicardial coronary artery, and OSA was assessed by polysomnography. The detailed exclusion criteria were as follows: intra-aortic balloon pump or other hemodynamic support devices; known OSA on continuous positive airway pressure (CPAP) treatment; intubation for mechanical ventilation; sedation given before overnight sleep study; cardiogenic shock with systolic blood pressure \<90 mmHg (1 mmHg = 0.133 kPa); clinical heart failure requiring oxygen supplement; perceived high risk of malignant ventricular arrhythmia; pregnancy; history of malignancy; the inability to provide informed consent; and expected lifespan \<12 months. Ninety-eight candidates were excluded from the present study due to receiving ticagrelor or disagreement of platelet function test. Hence, a total of 242 patients undergoing DES implantation were included in the subgroup analysis of association between platelet reactivity and OSA.

Percutaneous coronary intervention and polysomnography {#sec2-3}
------------------------------------------------------

All interventional procedures were performed in accordance with current guidelines. A loading dose of clopidogrel (300 mg) was administered before the index procedure. Use of glycoprotein IIb/IIIa inhibitors was at operator\'s discretion. Routine blood tests, hepatorenal function, lipid profile, and ultrasonic cardiogram were examined before coronary angiography. After intervention, all patients received 100 mg/d aspirin indefinitely and 75 mg/d clopidogrel for at least 12 months.

All data from overnight polysomnography screening, which is the gold standard for OSA diagnosis,\[[@ref8]\] were collected and stored on the Embletta Gold standardized level-3 portable diagnostic system (Natus Medical Inc., Ontario, Canada). Recorded polysomnographic signals included nasal airflow, thoracoabdominal excursions, arterial oxygen saturation (SpO~2~), snoring episodes, limb movement, electrocardiogram, and body position. All sleep studies were manually analyzed by two independent sleep technologists with registered polysomnographic technologist credentials, and disagreement was resolved by a third technologist. The primary measure of the sleep study was the apnea-hypopnea index (AHI), quantified as the total number of apnea and hypopnea episodes per hour of sleep. Apnea was defined as a ≥90% decrease in airflow from baseline value for ≥10 s. Hypopnea was defined as a 30--90% reduction in airflow from baseline value lasting ≥10 s, in conjunction with ≥3% oxygen desaturation. The respiratory events of sleep study were performed per standard criteria, and all enrolled patients had moderate-to-severe OSA (AHI \>15 events/h) and none mild OSA (AHI ≤15 events/h).

Blood collection and platelet function test {#sec2-4}
-------------------------------------------

Antecubital vein blood samples were collected in 3.2% sodium citrate tubes (Becton-Dickinson, Franklin Lakes, New Jersey, USA) before intraprocedural heparin administration at the catheterization laboratory. Blood samples were stored at room temperature and tested within 2 h after collection.

Platelet reactivity was assessed with a sequential platelet counting method by PL-11 (SINNOWA Medical Science & Technology Co., Nanjing, China).\[[@ref9]\] The whole procedure was automatically performed within 15 min after transferring 500 μl citrated blood sample into a polycarbonate tube and inserting it into the detection position. Arachidonic acid (AA, 2 mg/ml) and adenosine diphosphate (ADP, 50 μmol/L) were automatically trickled into the blood sample as aggregation inducers after second detection time. PL-11 counted platelet several times until it detected the lowest level. The maximum aggregation ratio (MAR) was calculated according to the following formula: MAR = 100 − (\[1^st^ platelet count − 2^nd^ platelet count\]/2 − lowest platelet count) × 100%. The average aggregation ratio (AAR) was calculated as follows: AAR = (max MAR + min MAR)/2. In addition, high platelet reactivity (HPR) on aspirin was defined as MAR% ≥30%, while HPR on clopidogrel was defined as MAR% ≥55% according to the preclinical data.

Statistical analysis {#sec2-5}
--------------------

Continuous variables are presented as means ± standard deviation (SD) or median (Q1, Q3) and were compared using the Student\'s *t*-test (for normal distribution) and Mann-Whitney *U*-test (for nonnormal distribution). Categorical variables are expressed as frequencies or percentages and were compared by Chi-square statistics or Fisher\'s exact test. Diagnostic accuracy of AHI for HPR on aspirin and clopidogrel was evaluated using receiver operating characteristic curve analysis, with optimal cutoff values of AHI identified by the Youden\'s index (sensitivity + specificity−1). Multivariable logistic regression was used to determine the independent predictors of HPR on aspirin and clopidogrel with purposeful selection of covariates. Variables associated with univariate analysis (all with *P* ≤0.1) and those judged to be of clinical importance from previously published reports were eligible for inclusion in the multivariable model-building process. All tests were two sided. Data were analyzed using SPSS software (version 22.0, SPSS Institute Inc., Chicago, USA) and a *P* \< 0.05 was considered statistically significant.

R[ESULTS]{.smallcaps} {#sec1-3}
=====================

Baseline clinical, laboratory, and angiographic characteristics {#sec2-6}
---------------------------------------------------------------

A total of 242 patients (aged 41--89 years) were finally enrolled in this study, and their baseline clinical characteristics are shown in [Table 1](#T1){ref-type="table"}. Patients were assigned based on AHI to the non-OSA (*n* = 128) and OSA (*n* = 114) groups. Baseline clinical characteristics between these two groups were well matched, except for higher body mass index (25.4 ± 3.0 kg/m^2^ vs. 24.5 ± 3.3 kg/m^2^, *t* = 4.342, *P* = 0.038) and higher white blood cell count (7.0 ± 1.9 × 10^9^/L vs. 6.5 ± 1.7 × 10^9^/L, *t* = 2.329, *P* = 0.020) in the OSA versus non-OSA groups. In [Table 1](#T1){ref-type="table"}, it showed that more patients in the OSA group had multivessel disease (68.4% vs. 53.1%, *χ*^2^ = 5.992, *P* = 0.015) than non-OSA group.

###### 

Baseline clinical and laboratory characteristics of percutaneous coronary intervention patients

  Characteristics                               Non-OSA (*n* = 128)   OSA (*n* = 114)   *t*/*χ*^2^   *P*
  --------------------------------------------- --------------------- ----------------- ------------ -------
  Clinical characteristics                                                                           
   Age (years) , mean ± SD                      63.1 ± 10.1           65.4 ± 10.2       2.981\*      0.086
   Male, *n* (%)                                93 (72.7)             92 (80.7)         2.169^†^     0.142
   BMI (kg/m^2^), mean ± SD                     24.5 ± 3.3            25.4 ± 3.0        4.342\*      0.038
   Smoking, *n* (%)                             62 (46.9)             53 (46.5)         0.921^†^     0.583
   Hypertension, *n* (%)                        91 (71.1)             85 (74.6)         0.363^†^     0.546
   SBP (mmHg), mean ± SD                        134.4 ± 19.9          132.6 ± 17.4      0.540\*      0.463
   DBP (mmHg), mean ± SD                        81.2 ± 9.6            80.5 ± 9.3        0.255\*      0.614
   Hyperlipidemia, *n* (%)                      80 (62.5)             79 (69.9)         1.465^†^     0.227
   Diabetes, *n* (%)                            33 (25.8)             37 (32.5)         1.303^†^     0.254
   LVEF (%)                                     61.2 ± 7.8            59.6 ± 10.2       1.426\*      0.866
   Previous MI, *n* (%)                         12 (9.4)              15 (13.2)         0.866^†^     0.352
   Previous PCI, *n* (%)                        20 (15.6)             24 (21.1)         1.190^†^     0.276
   Previous CABG, *n* (%)                       1 (0.8)               1 (0.9)           0.007^†^     0.935
   Stroke, *n* (%)                              16 (12.5)             12 (10.5)         0.228^†^     0.633
   PAD, *n* (%)                                 1 (0.8)               4 (3.5)           1.974^†^     0.161
   eGFR \<60 ml·min^−1^·1.73 m^−2^, *n* (%)     26 (20.3)             26 (23.0)         0.014^†^     0.612
  Laboratory characteristics                                                                         
   WBC (×10^9^/L), mean ± SD                    6.5 ± 1.7             7.0 ± 1.9         2.329\*      0.020
   RBC (×10^12^/L), mean ± SD                   4.2 ± 0.5             4.4 ± 0.5         1.739\*      0.082
   Hemoglobin (g/L), mean ± SD                  130.9 ± 16.7          135.9 ± 16.0      1.730\*      0.084
   Platelet (×10^9^/L), mean ± SD               186.4 ± 58.1          188.7 ± 52.8      0.347\*      0.729
   Serum creatinine (µmol/L), mean ± SD         81.0 ± 30.2           83.0 ± 28.1       1.168\*      0.243
   Glucose (mmol/L), mean ± SD                  5.9 ± 1.8             6.2 ± 2.3         0.584\*      0.559
   Cholesterol (mmol/L), mean ± SD              4.0 ± 1.0             3.9 ± 1.0         0.638\*      0.523
   Triglyceride (mmol/L), mean ± SD             1.7 ± 0.9             1.7 ± 1.1         0.549\*      0.583
   HDL-C (mmol/L), mean ± SD                    1.0 ± 0.2             1.0 ± 0.2         1.361\*      0.174
   LDL-C (mmol/L), mean ± SD                    2.4 ± 0.7             2.3 ± 0.8         0.756\*      0.450
   hsCRP (µg/ml), mean ± SD                     32.9 ± 9.5            31.6 ± 9.7        0.825\*      0.409
   IL-6 (pg/ml), mean ± SD                      10.7 ± 3.0            11.0 ± 2.9        0.645\*      0.519
  Angiographic and procedural characteristics                                                        
   Transradial, *n* (%)                         124 (96.9)            111 (97.4)        0.052^†^     0.820
   Multivessel disease, *n* (%)                 68 (53.1)             78 (68.4)         5.992^†^     0.015
   DES used, *n* (%)                            128 (100)             114 (100)         NA           NA
   Total implanted stents number, mean ± SD     1.8 ± 1.1             2.0 ± 1.0         0.970\*      0.326
   Mean stent diameter (mm), mean ± SD          2.9 ± 0.7             3.0 ± 0.6         0.187\*      0.666
   Total stent length (mm), mean ± SD           48.7 ± 29.5           51.0 ± 28.4       0.378\*      0.539
   Complete revascularization, *n* (%)          93 (72.7)             72 (63.2)         2.513^†^     0.114
   Final TIMI Grade 3, *n* (%)                  128 (100)             112 (98.2)        2.267^†^     0.133

1 mmHg = 0.133 kPa.\**t* values; ^†^ *χ*^2^ values. SD: Standard deviation; BMI: Body mass index; SBP: Systolic blood pressure; DBP: Diastolic blood pressure; LVEF: Left ventricular ejection fraction; MI: Myocardial infarction; PCI: Percutaneous coronary intervention; CABG: Coronary artery bypass grafting; PAD: Peripheral artery disease; eGFR: Estimated glomerular filtration rate; WBC: White blood cell; RBC: Red blood cell; HDL-C: High-density lipoprotein cholesterol; LDL-C: Low-density lipoprotein cholesterol; hsCRP: High-sensitivity C-reactive protein; IL-6: Interleukin-6; DES: Drug-eluting stent; TIMI: Thrombolysis in myocardial infarction; OSA: Obstructive sleep apnea; NA: Not applicable.

Sleep study {#sec2-7}
-----------

The sleep characteristics are shown in [Table 2](#T2){ref-type="table"}. All enrolled patients received an overnight sleep study for about 409 min (Z = −0.672, *P* = 0.501 for two groups). The median AHI in the OSA group was 34.5 events/h, significantly higher than the non-OSA group (8.1 events/h, *Z* = −13.422, *P* \< 0.001). Patients in the OSA group had significantly lower average and lowest arterial oxygen saturation (SpO~2~; average SpO~2~: 93.2% \[92.1%, 94.2%\] vs. 93.9% \[93.0%, 94.8%\], *Z* = −3.264, *P* = 0.001; lowest SpO~2~: 82.0% \[79.0%, 85.0%\] vs. 87.0% \[82.0%, 89.0%\], *Z* = −5.720, *P* \< 0.001) and higher total percentage of time SpO~2~ \<90% (16.5% vs. 2.7%, *Z* = −5.825, *P* \< 0.001), compared to those in the non-OSA group.

###### 

Sleep characteristics of percutaneous coronary intervention patients

  Characteristics                         Non-OSA (*n* = 128)    OSA (*n* = 114)        *Z*       *P*
  --------------------------------------- ---------------------- ---------------------- --------- ---------
  AHI                                     8.1 (3.9, 11.6)        34.5 (23.2, 47.7)      −13.422   \<0.001
  Index time (min)                        409.2 (398.7, 414.2)   408.8 (388.1, 414.3)   −0.672    0.501
  SpO~2~ (%)                              93.9 (93.0, 94.8)      93.2 (92.1, 94.2)      −3.264    0.001
  OD (events/h)                           3.2 (1.0, 6.1)         19.0 (9.7, 35.2)       −10.549   \<0.001
  Snore time (min)                        2.4 (0.5, 11.7)        5.3 (0.8, 18.1)        −0.905    0.365
  Snore episodes, *n*                     27.0 (8.0, 109.0)      69.0 (11.0, 167.0)     −1.818    0.069
  Total percentage of time SpO~2~ \<90%   2.7 (0.4, 17.3)        16.5 (7.2, 50.7)       −5.825    \<0.001
  Lowest SpO~2~ (%)                       87.0 (82.0, 89.0)      82.0 (79.0, 85.0)      −5.720    \<0.001
  Snoring time (min)                      8.5 (1.5, 52.4)        21.6 (2.8, 65.1)       −0.965    0.335
  Number of snoring                       26.0 (0.7, 109.0)      69.0 (11.0, 167.0)     −1.901    0.057
  Longest snoring (min)                   1.2 (0.5, 3.9)         1.7 (0.7, 4.7)         −1.227    0.220

Data are shown as median (Q1, Q3). AHI: Apnea-hypopnea index; OD: Obstructive desaturation; SpO~2~: Arterial oxygen saturation; OSA: Obstructive sleep apnea.

Obstructive sleep apnea and platelet reactivity {#sec2-8}
-----------------------------------------------

As shown in [Figure 1](#F1){ref-type="fig"}, the median AA-induced MAR of 21.1% (15.1%, 28.7%) and ADP-induced MAR of 45.8% (34.4%, 56.5%) in the OSA group were significantly higher than those in the non-OSA group (AA-MAR: 17.7% \[13.4%, 22.6%\], *Z* = −3.525, *P* \< 0.001; ADP-MAR: 32.2% \[23.6%, 40.3%\], *Z* = −5.708, *P* \< 0.001). Moreover, the median AA-induced AAR of 14.2% (10.5%, 19.4%) and ADP-induced AAR of 36.6% (26.8%, 45.6%) and 25.4% (18.5%, 32.6%) in the OSA group were higher than those in the non-OSA group identically (ADP-AAR: 12.5% \[8.7%, 15.5%\], *Z* = −3.355, *P* = 0.001 and ADP-AAR: 25.4% \[18.5%, 32.6%\], *Z* = −5.693, *P* \< 0.001). There was a moderate correlation (*r* = 0.412, *P* \< 0.001) between ADP-induced MAR and AHI and a weak correlation (*r* = 0.251, *P* \< 0.001) between AA-induced MAR and AHI. By multivariable logistic regression, OSA, as represented by AHI, appeared as the only independent predictor for HPR on aspirin (odds ratio \[*OR*\]: 1.055, 95% confidence interval \[*CI*\]: 1.033--1.077, *P* \< 0.001; [Table 3](#T3){ref-type="table"}) and HPR on clopidogrel (*OR*: 1.036, 95% *CI*: 1.017--1.056, *P* \< 0.001).

![Platelet activation test parameters from PL-11 in OSA (*n* = 114) and non-OSA (*n* = 128) groups. (a) AA-induced MAR in non-OSA and OSA groups. (b) AA-induced AAR in non-OSA and OSA groups. (c) ADP-induced MAR in non-OSA and OSA groups. (d) ADP-induced AAR in non-OSA and OSA groups. OSA: Obstructive sleep apnea; AA: Arachidonic acid; MAR: Maximum aggregation rate; AAR: Average aggregation rate; ADP: Adenosine diphosphate.](CMJ-131-1023-g001){#F1}

###### 

Multivariate analyses of high platelet reactivity on aspirin and clopidogrel of percutaneous coronary intervention patients

  Factors                                   *OR* (95% *CI*)        *P*
  ----------------------------------------- ---------------------- ---------
  High platelet reactivity on aspirin                              
    Age                                     0.987 (0.945--1.030)   0.540
    Smoking                                 1.038 (0.562--1.916)   0.906
    Hyperlipidemia                          0.975 (0.403--2.359)   0.955
    Diabetes                                0.893 (0.361--2.209)   0.806
    eGFR                                    1.000 (0.985--1.015)   0.991
    OSA                                     1.055 (1.033--1.077)   \<0.001
  High platelet reactivity on clopidogrel                          
    Age                                     0.982 (0.945--1.020)   0.342
    Smoking                                 0.957 (0.543--1.686)   0.879
    Hyperlipidemia                          1.331 (0.595--2.978)   0.486
    Diabetes                                2.012 (0.933--4.337)   0.074
    eGFR                                    1.010 (0.998--1.022)   0.106
    OSA                                     1.036 (1.017--1.056)   \<0.001

*OR*: Odds ratio; *CI*: Confidence interval; eGFR: Estimated glomerular filtration rate; OSA: Obstructive sleep apnea.

As shown in [Figure 2](#F2){ref-type="fig"}, the area under the curve (AUC) of AHI for HPR on aspirin was 0.760 (95% *CI*: 0.670--0.850, *P* \< 0.001), with cutoff value of 45.2 events/h (sensitivity 47.1% and specificity 91.3%), whereas the AUC of AHI for HPR on clopidogrel was 0.724 (95% *CI*: 0.645--0.803, *P* \< 0.001), with cutoff value of 21.3 events/h (sensitivity 68.3% and specificity 67.7%).

![Receiver operating characteristic curve analyses of platelet function parameters for diagnosis of antiplatelet treatment. (a) Receiver operating characteristic analysis for aspirin resistance. (b) Receiver operating characteristic analysis for clopidogrel resistance.](CMJ-131-1023-g002){#F2}

D[ISCUSSION]{.smallcaps} {#sec1-4}
========================

To the best of our knowledge, few studies have explored the association between OSA and platelet reactivity in patients undergoing DES implantation. The major novel findings from the present evaluation were: (1) platelet aggregation was activated in OSA patients with DES implantation, despite the loading dose of aspirin and clopidogrel, which might underlie the increased risk of stent thrombosis in OSA patients after coronary intervention; (2) OSA might be an independent predictor of HPR on aspirin and clopidogrel; and (3) the cutoff value of AHI for HPR on aspirin was 45.2 events/h (sensitivity 47.1% and specificity 91.3%) and the cutoff value of AHI for HPR on clopidogrel was 21.3 events/h (sensitivity 68.3% and specificity 67.7%).

OSA is a common disease worldwide, with prevalence among adults ranging from 5% to 14%, which is often underestimated due to a lack of awareness and limited access to polysomnography.\[[@ref10]\] Chronic intermittent hypoxia is the significant feature in OSA, which is associated with increased risk of secondary cardiovascular disease. Moreover, OSA is also an independent risk factor for hypertension, CAD, atrial fibrillation, cardiac failure, and stroke. In our previous study,\[[@ref3]\] about 45% of patients with DES implantation had moderate-to-severe OSA, and OSA was associated with significantly increased 2-year composite MACE rate. However, the underlying mechanisms of OSA-induced atherosclerosis remain unclear, and platelet aggregation and activation underlie occurrence and development of atherosclerosis. The previous clinical study showed that platelet activation was associated with greater levels of oxygen desaturation in obese patients with OSA.\[[@ref4]\] Another clinical study also indicated that the severity of OSA significantly contributed to platelet aggregability, which was partially improved by CPAP treatment at 3 months.\[[@ref11]\] The review by Liak and Fitzpatrick\[[@ref12]\] documented that hematocrit, blood viscosity, certain clotting factors, tissue factor, platelet activity, and whole blood coagulability were increased in patients with OSA, while fibrinolysis was impaired. In addition, it has been reported that elevated epinephrine and fibrinogen levels in OSA induced binding to the glycoprotein IIb/IIIa complex on the platelet surface, leading to platelet aggregation and activation.\[[@ref13]\] In summary, there is considerable evidence on the association between OSA and a procoagulant state, and OSA patients have abnormal platelet aggregation and activation.

Despite the aforementioned observations, there has been a paucity of evidence on the association between OSA and platelet activity in patients with DES implantation. As is well known, platelets take part in the occurrence and development of atherosclerosis and thrombosis, especially promoting the instability and rupture of atheromatous plaque in acute coronary syndrome. Hence, platelet inhibitors, for example, aspirin and clopidogrel,\[[@ref14]\] are the cornerstones of treatment of CAD, particularly with coronary stent implantation. Despite the well-documented efficacy of antiplatelet agents, recurrent thrombotic events, particularly stent thrombosis, have been repeatedly demonstrated in stented patients. One of the most important reasons underlying stent thrombosis might be inadequate platelet aggregation and activation inhibition. The present clinical study demonstrated that platelet aggregation was activated in OSA patients with DES implantation despite the routine use of aspirin and clopidogrel, and OSA might be a potential predictor for HPR on aspirin and clopidogrel, which has been confirmed to be associated with increased risk of stent thrombosis.\[[@ref15]\] The latter observation might explain why OSA has been independently associated with subsequent stent thrombosis and other adverse cardiac and cerebrovascular events in patients undergoing PCI.\[[@ref3][@ref16]\] To this end, the type of antiplatelet agents could be switched, or dosage doubled in OSA patients to achieve a similar antiplatelet effect, which should be verified by further well-designed clinical studies.

There were several limitations in this study. First, none of the 242 patients had received treatments for OSA, and it was not possible to evaluate the effects of CPAP treatment on platelet reactivity. Second, patients were not retested for sleep data and platelet reactivity during follow-up. Third, platelet reactivity was assessed with a sequential platelet counting method by PL-11, which has been demonstrated to be correlated with light transmittance aggregometry and VerifyNow.\[[@ref9]\] Fourth, apart from platelet reactivity, other parameters such as MPV, platelet distribution width as well as platelet-large cell rate were not assessed in the present study. Fifth, the present study was the cross-sectional design, which limited the clinical importance of this study.

In conclusion, despite a loading dose of aspirin and clopidogrel, platelet aggregation was activated in OSA patients undergoing DES implantation, and OSA might be an independent predictor of HPR on aspirin and clopidogrel. Appropriately powered clinical trials are necessary to confirm the findings from this study.
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